The best alternative to Ozempic for weight loss is Wegovy — the same molecule (semaglutide) at a higher dose, FDA-approved specifically for weight management. Other strong options include Zepbound (tirzepatide), Contrave, phentermine, and Saxenda.
Why look beyond Ozempic for weight loss
Ozempic is FDA-approved for type 2 diabetes, not weight loss. Using it off-label for weight management creates three practical problems:
- Insurance. Most plans won’t cover Ozempic without a diabetes diagnosis. Out-of-pocket cost is often high.
- Dosing. Ozempic maxes out at 2.0 mg. Wegovy, the weight-loss version, goes to 2.4 mg — the dose studied in the landmark STEP trials.
- Supply priority. Ozempic production prioritizes patients with type 2 diabetes. Using it off-label for weight loss diverts supply from those who depend on it.
The good news: every mechanism available in Ozempic is available in an FDA-approved weight loss medication, plus several additional options.
Best alternatives to Ozempic
1. Wegovy (semaglutide 2.4 mg)
Same active ingredient as Ozempic at a higher weight-loss dose. FDA-approved for chronic weight management. Also FDA-approved for cardiovascular risk reduction (MACE). This is the most direct “alternative” — it’s literally the weight loss version of the same drug.
2. Zepbound (tirzepatide)
A dual GIP/GLP-1 receptor agonist that produces more weight loss than semaglutide in clinical trials (~22.5% vs. ~15%). FDA-approved for weight loss and obstructive sleep apnea. Made by Eli Lilly. In clinical trials, it has produced the most weight loss of any currently FDA-approved anti-obesity medication.
3. Contrave (naltrexone/bupropion)
An oral medication that targets the brain’s reward pathways rather than gut hormones. Best for patients whose weight gain is driven by cravings, emotional eating, or food reward behavior. Produces less weight loss (~5–6%) but addresses a mechanism GLP-1s don’t.
4. Phentermine
A short-term appetite suppressant that’s been available for decades. Usually very affordable. Useful as a kickstart, bridge therapy, or step therapy requirement. Not for long-term use.
5. Saxenda (liraglutide 3.0 mg)
A daily GLP-1 injection approved for weight loss. Less effective than Wegovy or Zepbound but an option when those aren’t available or tolerated. Requires daily injection rather than weekly.
Quick comparison
| Medication | Class | Avg Weight Loss | Administration | Approx. Cost |
|---|---|---|---|---|
| Wegovy | GLP-1 | ~15% | Weekly injection | Insurance or self-pay |
| Zepbound | GIP/GLP-1 | ~22.5% | Weekly injection | Insurance or self-pay |
| Contrave | Opioid antagonist/NDRI | ~5–6% | Oral, twice daily | Varies by plan/pharmacy |
| Phentermine | Sympathomimetic | 5–10% | Oral, daily | Often low cost |
| Saxenda | GLP-1 | ~8% | Daily injection | Insurance or self-pay |
How to choose
- Wegovy — semaglutide at the proper weight-loss dose with CV benefit
- Zepbound — dual mechanism produces the most weight loss in trials
- Contrave — targets reward pathways GLP-1s don’t address
- Phentermine — often low cost, effective short-term appetite suppression
Important safety information: All GLP-1 and GIP/GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda) carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. They are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your medical history with your clinician before starting any GLP-1 medication.
PEAK’s approach
PEAK prescribes all five of these alternatives. We do not prescribe Ozempic for weight loss because every semaglutide benefit is available through Wegovy, the medication designed for weight management.
Your clinician will evaluate your health profile, eating patterns, insurance coverage, and goals to recommend the best starting point. Many patients try more than one medication before finding their best fit. That’s normal, and we support you through the process. Schedule a consultation.
